Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of “Hold” from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received a consensus recommendation of “Hold” from the twenty-three brokerages that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $20.98.

Several research analysts recently issued reports on the company. Wedbush lifted their target price on Intellia Therapeutics from $12.00 to $13.00 and gave the company a “neutral” rating in a research report on Wednesday, September 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a research report on Friday, July 17th. Evercore upgraded Intellia Therapeutics from a “hold” rating to an “outperform” rating and set a $24.00 price objective on the stock in a research note on Friday, August 7th. Wolfe Research downgraded shares of Intellia Therapeutics from a “peer perform” rating to an “underperform” rating and set a $9.00 price objective on the stock. in a report on Wednesday, July 15th. Finally, New Street Research set a $25.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 15th.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $11.75 on Tuesday. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -3.50 and a beta of 1.82. Intellia Therapeutics has a fifty-two week low of $7.95 and a fifty-two week high of $28.25. The firm’s 50-day simple moving average is $11.97 and its 200 day simple moving average is $13.28.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting analysts’ consensus estimates of ($0.80). The firm had revenue of $7.66 million during the quarter, compared to analyst estimates of $12.98 million. Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%.The company’s revenue for the quarter was down 46.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.98) EPS. On average, sell-side analysts predict that Intellia Therapeutics will post -3.21 EPS for the current year.

Insider Activity

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,641 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $16.78, for a total value of $44,315.98. Following the completion of the sale, the chief accounting officer owned 66,886 shares in the company, valued at approximately $1,122,347.08. This trade represents a 3.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of Intellia Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $18.00, for a total transaction of $84,186.00. Following the transaction, the executive vice president directly owned 156,286 shares in the company, valued at approximately $2,813,148. This represents a 2.91% decrease in their position. The SEC filing for this sale provides additional information. 3.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several institutional investors have recently modified their holdings of NTLA. BlackRock Inc. bought a new stake in Intellia Therapeutics during the second quarter worth $260,721,000. Dimensional Fund Advisors LP increased its position in shares of Intellia Therapeutics by 20.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,318,110 shares of the company’s stock valued at $29,709,000 after purchasing an additional 386,261 shares during the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in shares of Intellia Therapeutics during the 1st quarter worth $17,913,000. Bank of America Corp DE raised its stake in shares of Intellia Therapeutics by 11.2% during the 1st quarter. Bank of America Corp DE now owns 1,381,703 shares of the company’s stock worth $17,713,000 after purchasing an additional 139,325 shares during the period. Finally, Armistice Capital LLC boosted its holdings in shares of Intellia Therapeutics by 72.0% in the 4th quarter. Armistice Capital LLC now owns 1,156,000 shares of the company’s stock worth $10,392,000 after buying an additional 484,000 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing curative treatments using CRISPR-based gene-editing technology. The company’s approach is designed to make targeted changes to disease-associated genes, including through in vivo therapies that edit genes directly inside the body.

Intellia’s pipeline includes NTLA-2001, an investigational treatment designed to address transthyretin amyloidosis by editing the TTR gene, and NTLA-2002, an investigational therapy targeting hereditary angioedema through editing of the KLKB1 gene.